Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Dr Mayer on PRO Data With Camizestrant Plus CDK4/6 Inhibition in ESR1+ Breast Cancer

November 5th 2025

Erica L. Mayer, MD, MPH, discussed PRO data in ESR1 mutation–emergent breast cancer following switch therapy to camizestrant plus a CDK4/6 inhibitor.

Dr Tarantino on the Efficacy of Neoadjuvant T-DXd/THP in High-Risk HER2+ Breast Cancer

November 5th 2025

Paolo Tarantino, MD, PhD, discussed the clinical implications of the DESTINY-Breast11 trial of T-DXd/THP in high-risk, HER2-positive early breast cancer.

Dr Tolaney on the Efficacy of T-DXd in HER2+ Breast Cancer in the Post-Neoadjuvant Setting

November 5th 2025

Sara M. Tolaney, MD, MPH, discussed the use of T-DXd in patients with HER2-positive breast cancer with residual disease after neoadjuvant therapy.

Dr Dent on the Potential Role of Dato-DXd for Immunotherapy-Ineligible TNBC

November 5th 2025

Rebecca Dent, MD, MSc, FRCP, discussed the future implications of data with first-line Dato-DXd in locally recurrent inoperable or metastatic TNBC.

Dr Kalinsky on the Importance of Novel Second-Line Therapies for HR+ Breast Cancer

November 5th 2025

Kevin Kalinsky, MD, MS, FASCO, discusses research needs to improve treatment strategies in the post-CDK4/6 inhibitor setting for HR-positive breast cancer.

JAK Inhibitor Selection and Sequencing Strategies Are Key in Myelofibrosis Management

November 5th 2025

Akriti Jain, MD, discusses treatment selection and sequencing of JAK inhibitors in myelofibrosis, emerging CALR-targeted research, and defining disease modification.

FDA Grants Orphan Drug Designation to M2T-CD33 for Acute Myeloid Leukemia

November 5th 2025

The FDA has granted orphan drug designation to M2T-CD33 for the treatment of patients with acute myeloid leukemia.

HER2DX Could Aid Chemotherapy Decision-Making in HER2+ Early-Stage Breast Cancer

November 5th 2025

HER2DX low-risk scores were associated with improved 10-year RFS and OS outcomes in older patients with HER2-positive early-stage breast cancer.

FDA Adds REMS Guidelines for Pexidartinib in Tenosynovial Giant Cell Tumor

November 5th 2025

The FDA has added REMS guidelines for the use of pexidartinib in tenosynovial giant cell tumor.

JAK Inhibitors Expand Treatment Options in Polycythemia Vera and Myelofibrosis

November 4th 2025

Akriti Jain, MD, highlights the evolving role of JAK inhibitors in managing polycythemia vera and myelofibrosis and efforts to optimize treatment sequencing.

Dr Lee on the Importance of Multidisciplinary Collaboration in NSCLC Management

November 4th 2025

Percy Lee, MD, discusses the critical nature of multidisciplinary collaboration and notes lingering questions about the optimal use of SABR in NSCLC.

Allogenic CAR T-Cell Therapy CB-011 Drives Responses in R/R Myeloma

November 4th 2025

CB-011 elicited responses in patients with relapsed/refractory multiple myeloma.

Meta Analysis Highlights Benefits of JAK Inhibitors vs BAT in Myelofibrosis

November 3rd 2025

Findings from a meta analysis showed that JAK inhibitors were associated with improved outcomes vs best available therapy in myelofibrosis.

Evolving Role of TKIs and Antibody-Based Strategies Refines Ph-Positive ALL Management

November 3rd 2025

Wendy Stock, MD, discusses how TKI-based, chemotherapy-free regimens are advancing Ph-positive ALL care toward durable, treatment-free remission.

Dr Jhaveri on the Association Between ADCs and Ocular Toxicities in Breast Cancer

October 31st 2025

Komal Jhaveri, MD, FACP, discusses ocular toxicities that can be seen with the use of ADCs when treating patients with breast cancer.

Dr Stock on the Multifaceted Role of Molecular Testing in Ph+ ALL

October 31st 2025

Wendy Stock, MD, discussed the role of molecular testing in Ph-positive ALL and best practices for implementing this testing across clinical scenarios.

Dr Dent on the Efficacy of First-Line Dato-DXd in TNBC

October 31st 2025

Rebecca Dent, MD, MSc, FRCP, discusses data from the TROPION-Breast02 trial of frontline Dato-DXd vs chemotherapy in locally recurrent metastatic TNBC.

Dr McCann on the Potential Clinical Utility of Gedatolisib in Advanced Breast Cancer

October 31st 2025

Kelly E. McCann, MD, PhD, discusses findings from the VIKTORIA-1 trial of gedatolisib-based regimens in hormone receptor–positive advanced breast cancer.

Dr Sidana on the FDA Approval of Belantamab Mafodotin Plus Vd in R/R Myeloma

October 31st 2025

Surbhi Sidana, MD, discusses belantamab mafodotin-blmf with bortezomib and dexamethasone for adult patients with relapsed or refractory multiple myeloma.

Mirvetuximab Soravtansine Receives Positive Reimbursement Recommendation From Canada’s Drug Agency for Platinum-Resistant Ovarian Cancer

October 31st 2025

Mirvetuximab soravtansine has received a positive reimbursement recommendation in Canada under the Target Zero initiative for platinum-resistant ovarian cancer.